Consistent with this trend is an analysis reported by Christopher Lee (Univ. California, Los Angeles). Upon mapping about a million human EST and mRNA sequences onto draft sequence, Lee found evidence of splicing in approximately 42% of full-length genes. Of those for which a function could be assigned, more than 75% mediate signal reception, transmission and cellular response to signal.
Positional cloners will instantly recognize the value of the human genome sequence as a labor-saving device. To wit: Eric Green (NHGRI) presented data supporting tumor-supressor activity of ST7, located at 7q31 (a locus implicated in conferring susceptibility to range of different cancers). They homed in on ST7 by eliminating other candidates in the contig sequenced by the Sequencing Consortium, followed by mutation screening of the two candidates that remained (see page 392).
Exploring expression. There are two, often coincident, goals of those who study global gene-expression patterns in cancer. One is the pursuit of new insights into the biology of cancer, in the belief that knowledge of the relevant pathways and players will lead to more effective strategies for treatment. The other regards data points, at least initially, as biologically neutral, with their (potential) value lying in the ability to partition samples in a clinically relevant manner. The two often overlap, as in the study presented by Louis Staudt (National Cancer Institute). In exploring the possibility that chronic lymphocytic leukemia (CLL) might be composed of two distinct diseases (it turns out that it is not), Staudt and colleagues also discovered that ZAP-70, a homolog of a signal transduction kinase, is expressed in CLL subtypes.
Anne-Marie Poustka (German Cancer Research Center) reported an association between gene expression and different stages of renal carcinomas. Refreshingly, she also acknowledged the many sources of 'noise' that can challenge analysis, and described how she gauged and computationally eliminated signal generated by PCR-plate artifact. The magnitude and prevalence of 'noise' is unknown, but it seems likely to challenge the reproduction of results between laboratories, and may become more obvious when a common, large and established repository permits comparison of closely related assays or (attempted) replicates. Alex Lash (NCBI) provided an update on one such repository, the Gene Expression Omnibus, which is now open for business and looking to increase its holdings to better test developing features.
Describing computational analysis to an audience of molecular bent is an unenviable task, although one made easier with the aid of a snazzy Powerpoint animation. Jeffrey Trent (NHGRI; co-organizer of the meeting) thus described the application of a combinatory approach, which allows one to predict the expression level of a given gene through combinations of other points in the data set. Given sufficient computing power (which can be had from IBM/NuTech) and data sets, it is conceivable that this approach will permit the validation and, perhaps, identification of transcriptional pathways. An unsupervised method of partitioning a single set of tissues into the most statistically significant subclasses-as demonstrated on a gene expression data set derived from a panel of 44 mixed prostate samples-was described by Amir Ben-Dor (Agilent).
Probing proteomics. As with genomics, proteomics is broad in scope. Beth Grayhack (Rochester Univ.) reported success in ascribing 14 different activities to specific genes over the past two years by screening pooled constructs. Each construct consists of a yeast open reading frame fused to glutathione S-transferase. Pools of 96 constructs are screened for a particular activity; wells yielding positive signal are plated out to identify the source fusion protein(s). The attraction of this approach is its speed; the challenge is that it relies heavily on robust assays and maintenance of relevant tertiary structure. Ruth VanBogelen (Pfizer) proposed the use of 2-D gel to obtain 'snapshots' of cellular physiology, analogous to the way in which gene-expression profiles are used, commenting that recently developed software for analyzing comparing protein gels permits BLAST-type searches across stored images. Also analagous to expression analysis is a method described by Ruedi Aebersold (Institute for Systems Biology), involving the use of two isotope-coded affinity tags and tandem mass spectrometry. The tags label proteins in two different cell types (or two cells of the same type but subjected to different conditions); mass spectrometry permits identification and comparative quantitation.
Structural genomics. Regular readers of these pages will be familiar with the strategy of bolstering the case for pathological effect of, say, a base substitution by sequence alignment or estimating effect on a structure predicted from a threading algorithm. Similarly, gene function is often hypothesized on the basis of sequence alignment. As structure can insinuate function and is often conserved in the absence of sequence homology, the case for a structural genomics project-the high-throughput analysis of structure-is a good one. Stephen Burley (Rockefeller Univ. and the New York Structural Genome Research Consortium (NYSGRC)) described the NYSGRC's strategy to streamline high-throughput structure determination, and a dilemma: with half a million protein sequences in the TrEMBL editorial protein database, and an estimated 2,000-5,000 different protein domains (or folds), how does one prioritize proteins for structure determination? The NSGRC has chosen to focus on proteins of medical relevance (and, along with four other consortia, was awarded four million dollars from the National Institute of General Medical Sciences for the first year of a 10-year program), with an eye to related, uncharacterized folds. For example, obtaining the structure of an enzyme in the cholesterol biosynthesis pathway should permit the modeling of 60 other TrEMBL entries. The ultimate aim of the structural genomics project, as described by Andrej Sali (Rockefeller Univ.; NYSGRC), is to put every protein sequence within modeling distance of a known structure.
Therapy. Patrick Brown (Stanford Univ.) proposed a therapeutic approach dubbed 'molecular stereotaxis' and tailored to the constellation of markers that defines the particular tumor in question. The model is an analog of stereotactic radiosurgery, which involves aiming radiation at a tumor from different angles. The tumor is always irradiated, as is normal tissue-but because irradiation is administered from different directions and converges on the tumor, the dose to normal tissue is much less than that to tumor. As with partitioning, this approach does not rely on an understanding of the underlying biology of the tumor, nor of the targets selected for attack.
A significant limitation to the implementation of this strategy, however, was described by Daniel Von Hoff (Univ. Arizona), who held the audience in rapt attention with his comments on 'clinomics'-which he defines as the application of 'oncogenomic' research. He noted the surge in the development of target-specific agents, and the anachronistic, unfortunate design of clinical trials and the approval procedures of the Food and Drug Administration. These are geared towards tumor type (for example, breast cancer), rather than marker status (for example, all tumors that express farnesoid X receptor).
A question of context. The 'picture' that is cancer resembles something that Picasso might have conceived at the peak of Cubism. Given the challenge of biological complexity, and the fact that the tools for dissection have been, and in many respects remain, crude-the attraction of a reductionist approach is easy to understand. It has also been vindicated by the clinically relevant partitioning of cancers according to expression profile.
Lynn Matrisian (Vanderbilt Univ.) described a range of data supporting a critical role for extracellular stroma in mediating tumor progression. This cautions against a stringently reductionist approach to analyzing tumors, a strategy eschewed by David Botstein (Stanford Univ.), who questioned the rationale of paring down tissue samples to eliminate, for example, blood vessels. He holds that the biology of a tumor is informed by its different components and that these should be included for an accurate gauge of molecular status and biology. This makes sense, although it is not clear that current methods of analysis will permit the identification of different components (not that this matters for 'blind' applications), or that tissues with a greater degree of heterogeneity will partition as cleanly as rigorously dissected samples. On the other hand, and assuming a robust partitioning algorithm, the use of heterogeneous samples may give rise to sub-partitions that would not otherwise be observed.
The acceleration of activity in genome research over the past 3-4 years has fueled the study of cancer, and was evident in many of the presentations. The 'young' , yet extremely promising nature of protein technologies was also clear. One would hope that, as the disciplines mature, it will become possible to combine different types of data obtained from different platforms, and sooner, rather than later. In the meantime, it is interesting to note that one of the most impressive advances in getting a grip on the treatment of cancer-that is, how to identify and target suitable markers for therapy-has come about with little knowledge of cancer biology.
